Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2757529 | 1.00 | ADORA2A (0.48) | ADORA2AADORA3ADORA1ADORA2BCDK1 | |
| SCHEMBL242249 | 1.00 | ADORA2A (0.48) | ADORA2AADORA3ADORA1ADORA2BCDK1 | |
| SCHEMBL242250 | 1.00 | ADORA2A (0.48) | ADORA2AADORA3ADORA1ADORA2BCDK1 | |
| SCHEMBL291922 | 0.94 | ADORA2A (0.56) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL291921 | 0.94 | ADORA2A (0.56) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL291920 | 0.94 | ADORA2A (0.56) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL242476 | 0.93 | ADORA2A (0.49) | ADORA2AADORA3ADORA1 | |
| SCHEMBL242477 | 0.93 | ADORA2A (0.49) | ADORA2AADORA3ADORA1 | |
| SCHEMBL242478 | 0.93 | ADORA2A (0.49) | ADORA2AADORA3ADORA1 | |
| SCHEMBL1402118 | 0.92 | ADORA2A (0.55) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | claimed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | claimed |
| EP-2322525-B1 | Purine derivatives for use as adenosin A2A receptor agonists | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | ADORA2A 2741/4885ADORA3 795/4885ADORA1 1271/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | ADORA2A 2741/4885ADORA3 795/4885ADORA1 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.